|
1
|
Chistiakov DA, Melnichenko AA, Myasoedova
VA, Grechko AV and Orekhov AN: Thrombospondins: A role in
cardiovascular disease. Int J Mol Sci. 18:E15402017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bornstein P: Thrombospondins as
matricellular modulators of cell function. J Clin Invest.
107:929–934. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bornstein P: Thrombospondins: Structure
and regulation of expression. FASEB J. 6:3290–3299. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Resovi A, Pinessi D, Chiorino G and
Taraboletti G: Current understanding of the thrombospondin-1
interactome. Matrix Biol. 37:83–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anilkumar N, Annis DS, Mosher DF and Adams
JC: Trimeric assembly of the C-terminal region of thrombospondin-1
or thrombospondin-2 is necessary for cell spreading and fascin
spike organisation. J Cell Sci. 115:2357–2366. 2002.PubMed/NCBI
|
|
6
|
Yu H, Tyrrell D, Cashel J, Guo NH, Vogel
T, Sipes JM, Lam L, Fillit HM, Hartman J, Mendelovitz S, et al:
Specificities of heparin-binding sites from the amino-terminus and
type 1 repeats of thrombospondin-1. Arch Biochem Biophys.
374:13–23. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elzie CA and Murphy-Ullrich JE: The
N-terminus of thrombospondin: The domain stands apart. Int J
Biochem Cell Biol. 36:1090–1101. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Feitsma K, Hausser H, Robenek H, Kresse H
and Vischer P: Interaction of thrombospondin-1 and heparan sulfate
from endothelial cells. Structural requirements of heparan sulfate.
J Biol Chem. 275:9396–9402. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kuznetsova SA, Day AJ, Mahoney DJ, Rugg
MS, Mosher DF and Roberts DD: The N-terminal module of
thrombospondin-1 interacts with the link domain of TSG-6 and
enhances its covalent association with the heavy chains of
inter-alpha-trypsin inhibitor. J Biol Chem. 280:30899–30908. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yan Q, Murphy-Ullrich JE and Song Y:
Structural insight into the role of thrombospondin-1 binding to
calreticulin in calreticulin-induced focal adhesion disassembly.
Biochemistry. 49:3685–3694. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kuznetsova SA, Issa P, Perruccio EM, Zeng
B, Sipes JM, Ward Y, Seyfried NT, Fielder HL, Day AJ, Wight TN and
Roberts DD: Versican-thrombospondin-1 binding in vitro and
colocalization in microfibrils induced by inflammation on vascular
smooth muscle cells. J Cell Sci. 119:4499–4509. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sweetwyne MT, Pallero MA, Lu A, Van Duyn
Graham L and Murphy-Ullrich JE: The calreticulin-binding sequence
of thrombospondin 1 regulates collagen expression and organization
during tissue remodeling. Am J Pathol. 177:1710–1724. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Murphy-Ullrich JE and Song Y:
Molecular insight into the effect of lipid bilayer environments on
thrombospondin-1 and calreticulin interactions. Biochemistry.
53:6309–6322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Orr AW, Pallero MA, Xiong WC and
Murphy-Ullrich JE: Thrombospondin induces RhoA inactivation through
FAK-dependent signaling to stimulate focal adhesion disassembly. J
Biol Chem. 279:48983–48992. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ndishabandi D, Duquette C, Billah GE,
Reyes M, Duquette M, Lawler J and Kazerounian S: Thrombospondin-1
modulates actin filament remodeling and cell motility in mouse
mammary tumor cells in vitro. Discoveries (Craiova). 2:e312014.
View Article : Google Scholar
|
|
16
|
Chandrasekaran L, He CZ, Al-Barazi H,
Krutzsch HC, Iruela-Arispe ML and Roberts DD: Cell
contact-dependent activation of alpha3beta1 integrin modulates
endothelial cell responses to thrombospondin-1. Mol Biol Cell.
11:2885–2900. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Furrer J, Luy B, Basrur V, Roberts DD and
Barchi JJ Jr: Conformational analysis of an alpha3beta1
integrin-binding peptide from thrombospondin-1: Implications for
antiangiogenic drug design. J Med Chem. 49:6324–6333. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brittain JE, Han J, Ataga KI, Orringer EP
and Parise LV: Mechanism of CD47-induced alpha4beta1 integrin
activation and adhesion in sickle reticulocytes. J Biol Chem.
279:42393–42402. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Calzada MJ, Sipes JM, Krutzsch HC,
Yurchenco PD, Annis DS, Mosher DF and Roberts DD: Recognition of
the N-terminal modules of thrombospondin-1 and thrombospondin-2 by
alpha-6beta1 integrin. J Biol Chem. 278:40679–40687. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bein K and Simons M: Thrombospondin type 1
repeats interact with matrix metalloproteinase 2. Regulation of
metalloproteinase activity. J Biol Chem. 275:32167–32173. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee T, Esemuede N, Sumpio BE and Gahtan V:
Thrombospondin-1 induces matrix metalloproteinase-2 activation in
vascular smooth muscle cells. J Vasc Surg. 38:147–154. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rodriguez-Manzaneque JC, Lane TF, Ortega
MA, Hynes RO, Lawler J and Iruela-Arispe ML: Thrombospondin-1
suppresses spontaneous tumor growth and inhibits activation of
matrix metalloproteinase-9 and mobilization of vascular endothelial
growth factor. Proc Natl Acad Sci USA. 98:12485–12490. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zeng T, Yuan J, Gan J, Liu Y, Shi L, Lu Z,
Xue Y, Xiong R, Huang M, Yang Z, et al: Thrombospondin 1 is
increased in the aorta and plasma of patients with acute aortic
dissection. Can J Cardiol. 35:42–50. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dawson DW, Pearce SF, Zhong R, Silverstein
RL, Frazier WA and Bouck NP: CD36 mediates the In vitro inhibitory
effects of thrombospondin-1 on endothelial cells. J Cell Biol.
138:707–717. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Silverstein RL and Febbraio M:
CD36-TSP-HRGP interactions in the regulation of angiogenesis. Curr
Pharm Des. 13:3559–3567. 2007. View Article : Google Scholar
|
|
26
|
Simantov R, Febbraio M and Silverstein RL:
The antiangiogenic effect of thrombospondin-2 is mediated by CD36
and modulated by histidine-rich glycoprotein. Matrix Biol.
24:27–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Crombie R and Silverstein R: Lysosomal
integral membrane protein II binds thrombospondin-1.
Structure-function homology with the cell adhesion molecule CD36
defines a conserved recognition motif. J Biol Chem. 273:4855–4863.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Calzada MJ, Annis DS, Zeng B,
Marcinkiewicz C, Banas B, Lawler J, Mosher DF and Roberts DD:
Identification of novel beta1 integrin binding sites in the type 1
and type 2 repeats of thrombospondin-1. J Biol Chem.
279:41734–41743. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goel HL, Moro L, Murphy-Ullrich JE, Hsieh
CC, Wu CL, Jiang Z and Languino LR: Beta1 integrin cytoplasmic
variants differentially regulate expression of the antiangiogenic
extracellular matrix protein thrombospondin 1. Cancer Res.
69:5374–5382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ahamed J, Janczak CA, Wittkowski KM and
Coller BS: In vitro and in vivo evidence that thrombospondin-1
(TSP-1) contributes to stirring- and shear-dependent activation of
platelet-derived TGF-beta1. PLoS One. 4:e66082009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kumar R, Mickael C, Kassa B, Gebreab L,
Robinson JC, Koyanagi DE, Sanders L, Barthel L, Meadows C, Fox D,
et al: TGF-β activation by bone marrow-derived thrombospondin-1
causes Schistosoma- and hypoxia-induced pulmonary hypertension. Nat
Commun. 8:154942017. View Article : Google Scholar
|
|
32
|
McGillicuddy FC, O’Toole D, Hickey JA,
Gallagher WM, Dawson KA and Keenan AK: TGF-beta1-induced
thrombospondin-1 expression through the p38 MAPK pathway is
abolished by fluvastatin in human coronary artery smooth muscle
cells. Vascul Pharmacol. 44:469–475. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takahashi K, Mernaugh RL, Friedman DB,
Weller R, Tsuboi N, Yamashita H, Quaranta V and Takahashi T:
Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase.
Proc Natl Acad Sci USA. 109:1985–1990. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Takahashi K, Sumarriva K, Kim R, Jiang R,
Brantley-Sieders DM, Chen J, Mernaugh RL and Takahashi T:
Determination of the CD148-interacting region in thrombospondin-1.
PLoS One. 11:e01549162016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Garg P, Yang S, Liu A, Pallero MA,
Buchsbaum DJ, Mosher DF, Murphy-Ullrich JE and Goldblum SE:
Thrombospondin-1 opens the paracellular pathway in pulmonary
microvascular endothelia through EGFR/ErbB2 activation. Am J
Physiol Lung Cell Mol Physiol. 301:L79–L90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rusnati M, Borsotti P, Moroni E, Foglieni
C, Chiodelli P, Carminati L, Pinessi D, Annis DS, Paiardi G,
Bugatti A, et al: The calcium-binding type III repeats domain of
thrombospondin-2 binds to fibroblast growth factor 2 (FGF2).
Angiogenesis. 22:133–144. 2019. View Article : Google Scholar
|
|
37
|
Kvansakul M, Adams JC and Hohenester E:
Structure of a thrombospondin C-terminal fragment reveals a novel
calcium core in the type 3 repeats. EMBO J. 23:1223–1233. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gupta A, Agarwal R, Singh A and Bhatnagar
S: Calcium-induced conformational changes of Thrombospondin-1
signature domain: Implications for vascular disease. J Recept
Signal Transduct Res. 37:239–251. 2017. View Article : Google Scholar
|
|
39
|
Joo SJ: Mechanisms of platelet activation
and integrin αIIβ3. Korean Circ J. 42:295–301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Freyberg MA, Kaiser D, Graf R,
Buttenbender J and Friedl P: Proatherogenic flow conditions
initiate endothelial apoptosis via thrombospondin-1 and the
integrin-associated protein. Biochem Biophys Res Commun.
286:141–149. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Freyberg MA, Kaiser D, Graf R, Vischer P
and Friedl P: Integrin-associated protein and thrombospondin-1 as
endothelial mechanosensitive death mediators. Biochem Biophys Res
Commun. 271:584–588. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
McDonald JF, Dimitry JM and Frazier WA: An
amyloid-like C-terminal domain of thrombospondin-1 displays CD47
agonist activity requiring both VVM motifs. Biochemistry.
42:10001–10011. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rath GM, Schneider C, Dedieu S, Rothhut B,
Soula-Rothhut M, Ghoneim C, Sid B, Morjani H, El Btaouri H and
Martiny L: The C-terminal CD47/IAP-binding domain of
thrombospondin-1 prevents camptothecin- and doxorubicin-induced
apoptosis in human thyroid carcinoma cells. Biochim Biophys Acta.
1763:1125–1134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pimanda JE, Annis DS, Raftery M, Mosher
DF, Chesterman CN and Hogg PJ: The von Willebrand factor-reducing
activity of thrombospondin-1 is located in the
calcium-binding/C-terminal sequence and requires a free thiol at
position 974. Blood. 100:2832–2838. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schultz-Cherry S, Chen H, Mosher DF,
Misenheimer TM, Krutzsch HC, Roberts DD and Murphy-Ullrich JE:
Regulation of transforming growth factor-beta activation by
discrete sequences of thrombospondin 1. J Biol Chem. 270:7304–7310.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen H, Sottile J, Strickland DK and
Mosher DF: Binding and degradation of thrombospondin-1 mediated
through heparan sulphate proteoglycans and low-density-lipoprotein
receptor-related protein: Localization of the functional activity
to the trimeric N-terminal heparin-binding region of
thrombospondin-1. Biochem J. 318:959–963. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Befekadu R, Christiansen K, Larsson A and
Grenegard M: Increased plasma cathepsin S and trombospondin-1 in
patients with acute ST segment elevation myocardial infarction.
Cardiol J. 26:385–393. 2019. View Article : Google Scholar
|
|
48
|
Kaiser R, Grotemeyer K, Kalsch T, Graber
S, Wilkens H and Elmas E: Decreased TSP-1 following percutaneous
coronary intervention is associated with major adverse cardiac
events in ST-elevation myocardial infarction. Clin Hemorheol
Microcirc. 54:59–73. 2013. View Article : Google Scholar
|
|
49
|
Sezaki S, Hirohata S, Iwabu A, Nakamura K,
Toeda K, Miyoshi T, Yamawaki H, Demircan K, Kusachi S, Shiratori Y,
et al: Thrombospondin-1 is induced in rat myocardial infarction and
its induction is accelerated by ischemia/reperfusion. Exp Biol Med
(Maywood). 230:621–630. 2005. View Article : Google Scholar
|
|
50
|
Frangogiannis NG, Ren G, Dewald O, Zymek
P, Haudek S, Koerting A, Winkelmann K, Michael LH, Lawler J and
Entman ML: Critical role of endogenous thrombospondin-1 in
preventing expansion of healing myocardial infarcts. Circulation.
111:2935–2942. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jugdutt BI: Ventricular remodeling after
infarction and the extracellular collagen matrix: When is enough
enough? Circulation. 108:1395–1403. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
van Oorschot AA, Smits AM, Pardali E,
Doevendans PA and Goumans MJ: Low oxygen tension positively
influences cardiomyocyte progenitor cell function. J Cell Mol Med.
15:2723–2734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ashokkumar M, Anbarasan C, Saibabu R,
Kuram S, Raman SC and Cherian KM: An association study of
thrombospondin 1 and 2 SNPs with coronary artery disease and
myocardial infarction among South Indians. Thromb Res. 128:e49–e53.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Koch W, Hoppmann P, de Waha A, Schomig A
and Kastrati A: Polymorphisms in thrombospondin genes and
myocardial infarction: A case-control study and a meta-analysis of
available evidence. Hum Mol Genet. 17:1120–1126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang XJ, Wei CY, Li WB, Zhang LL, Zhou Y,
Wang ZH, Tang MX, Zhang W, Zhang Y and Zhong M: Association between
single nucleotide polymorphisms in thrombospondins genes and
coronary artery disease: A meta-analysis. Thromb Res. 136:45–51.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zwicker JI, Peyvandi F, Palla R, Lombardi
R, Canciani MT, Cairo A, Ardissino D, Bernardinelli L, Bauer KA,
Lawler J and Mannucci P: The thrombospondin-1 N700S polymorphism is
associated with early myocardial infarction without altering von
Willebrand factor multimer size. Blood. 108:1280–1283. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhou X, Huang J, Chen J, Zhao J, Ge D,
Yang W and Gu D: Genetic association analysis of myocardial
infarction with thrombospondin-1 N700S variant in a Chinese
population. Thromb Res. 113:181–186. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Abdelmonem NA, Turky NO, Hashad IM, Abdel
Rahman MF, El-Etriby A and Gad MZ: Association of thrombospondin-1
(N700S) and thrombospondin-4 (A387P) gene polymorphisms with the
incidence of acute myocardial infarction in egyptians. Curr Pharm
Biotechnol. 18:1078–1087. 2017. View Article : Google Scholar
|
|
59
|
Stenina OI, Ustinov V, Krukovets I,
Marinic T, Topol EJ and Plow EF: Polymorphisms A387P in
thrombospondin-4 and N700S in thrombospondin-1 perturb calcium
binding sites. FASEB J. 19:1893–1895. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Xia Y, Dobaczewski M, Gonzalez-Quesada C,
Chen W, Biernacka A, Li N, Lee DW and Frangogiannis NG: Endogenous
thrombospondin 1 protects the pressure-overloaded myocardium by
modulating fibroblast phenotype and matrix metabolism.
Hypertension. 58:902–911. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Gonzalez-Quesada C, Cavalera M, Biernacka
A, Kong P, Lee DW, Saxena A, Frunza O, Dobaczewski M, Shinde A and
Frangogiannis NG: Thrombospondin-1 induction in the diabetic
myocardium stabilizes the cardiac matrix in addition to promoting
vascular rarefaction through angiopoietin-2 upregulation. Circ Res.
113:1331–1344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Swinnen M, Vanhoutte D, Van Almen GC,
Hamdani N, Schellings MW, D’hooge J, Van der Velden J, Weaver MS,
Sage EH, Bornstein P, et al: Absence of thrombospondin-2 causes
age-related dilated cardiomyopathy. Circulation. 120:1585–1597.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
van Almen GC, Swinnen M, Carai P, Verhesen
W, Cleutjens JP, D’hooge J, Verheyen FK, Pinto YM, Schroen B,
Carmeliet P and Heymans S: Absence of thrombospondin-2 increases
cardiomyocyte damage and matrix disruption in doxorubicin-induced
cardiomyopathy. J Mol Cell Cardiol. 51:318–328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Papageorgiou AP, Swinnen M, Vanhoutte D,
VandenDriessche T, Chuah M, Lindner D, Verhesen W, de Vries B,
D’hooge J, Lutgens E, et al: Thrombospondin-2 prevents cardiac
injury and dysfunction in viral myocarditis through the activation
of regulatory T-cells. Cardiovasc Res. 94:115–124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Schroen B, Heymans S, Sharma U,
Blankesteijn WM, Pokharel S, Cleutjens JP, Porter JG, Evelo CT,
Duisters R, van Leeuwen RE, et al: Thrombospondin-2 is essential
for myocardial matrix integrity: Increased expression identifies
failure-prone cardiac hypertrophy. Circ Res. 95:515–522. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Batlle M, Perez-Villa F, Lazaro A,
García-Pras E, Vallejos I, Sionis A, Castel MA and Roig E:
Decreased expression of thrombospondin-1 in failing hearts may
favor ventricular remodeling. Transplant Proc. 41:2231–2233. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Vila V, Martinez-Sales V, Almenar L,
Lazaro IS, Villa P and Reganon E: Inflammation, endothelial
dysfunction and angiogenesis markers in chronic heart failure
patients. Int J Cardiol. 130:276–277. 2008. View Article : Google Scholar
|
|
68
|
Sharifi-Sanjani M, Shoushtari AH, Quiroz
M, Baust J, Sestito SF, Mosher M, Ross M, McTiernan CF, St Croix
CM, Bilonick RA, et al: Cardiac CD47 drives left ventricular heart
failure through Ca2+-CaMKII-regulated induction of
HDAC3. J Am Heart Assoc. 3:e0006702014. View Article : Google Scholar
|
|
69
|
van Almen GC, Verhesen W, van Leeuwen RE,
van de Vrie M, Eurlings C, Schellings MW, Swinnen M, Cleutjens JP,
van Zandvoort MA, Heymans S and Schroen B: MicroRNA-18 and
microRNA-19 regulate CTGF and TSP-1 expression in age-related heart
failure. Aging Cell. 10:769–779. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Vila V, Sales VM, Almenar L, Lazaro IS,
Villa P and Reganon E: Effect of oral anticoagulant therapy on
thrombospondin-1 and von Willebrand factor in patients with stable
heart failure. Thromb Res. 121:611–615. 2008. View Article : Google Scholar
|
|
71
|
Berezin AE, Kremzer AA and Samura TA:
Circulating thrombospondine-2 in patients with moderate-to-severe
chronic heart failure due to coronary artery disease. J Biomed Res.
Mar 2–2015.[Epub ahead of print]. PubMed/NCBI
|
|
72
|
Kimura Y, Izumiya Y, Hanatani S, Yamamoto
E, Kusaka H, Tokitsu T, Takashio S, Sakamoto K, Tsujita K, Tanaka
T, et al: High serum levels of thrombospondin-2 correlate with poor
prognosis of patients with heart failure with preserved ejection
fraction. Heart Vessels. 31:52–59. 2016. View Article : Google Scholar
|
|
73
|
Hanatani S, Izumiya Y, Takashio S, Kimura
Y, Araki S, Rokutanda T, Tsujita K, Yamamoto E, Tanaka T, Yamamuro
M, et al: Circulating thrombospondin-2 reflects disease severity
and predicts outcome of heart failure with reduced ejection
fraction. Circ J. 78:903–910. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Freeman RV and Otto CM: Spectrum of
calcific aortic valve disease: Pathogenesis, disease progression,
and treatment strategies. Circulation. 111:3316–3326. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Pohjolainen V, Mustonen E, Taskinen P,
Näpänkangas J, Leskinen H, Ohukainen P, Peltonen T, Aro J, Juvonen
T, Satta J, et al: Increased thrombospondin-2 in human
fibrosclerotic and stenotic aortic valves. Atherosclerosis.
220:66–71. 2012. View Article : Google Scholar
|
|
76
|
Jurk K, Ritter MA, Schriek C, Van Aken H,
Droste DW, Ringelstein EB and Kehrel BE: Activated monocytes
capture platelets for heterotypic association in patients with
severe carotid artery stenosis. Thromb Haemost. 103:1193–1202.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Desai P, Helkin A, Odugbesi A, Stein J,
Bruch D, Lawler J, Maier KG and Gahtan V: Fluvastatin inhibits
intimal hyperplasia in wild-type but not Thbs1-null mice. J Surg
Res. 210:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Liauw J, Hoang S, Choi M, Eroglu C, Choi
M, Sun GH, Percy M, Wildman-Tobriner B, Bliss T, Guzman RG, et al:
Thrombospondins 1 and 2 are necessary for synaptic plasticity and
functional recovery after stroke. J Cereb Blood Flow Metab.
28:1722–1732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Lin TN, Kim GM, Chen JJ, Cheung WM, He YY
and Hsu CY: Differential regulation of thrombospondin-1 and
thrombospondin-2 after focal cerebral ischemia/reperfusion. Stroke.
34:177–186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yang AL, Zhou HJ, Lin Y, Luo JK, Cui HJ,
Tang T and Yang QD: Thrombin promotes the expression of
thrombospondin-1 and -2 in a rat model of intracerebral hemorrhage.
J Neurol Sci. 323:141–146. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhou HJ, Zhang HN, Tang T, Zhong JH, Qi Y,
Luo JK, Lin Y, Yang QD and Li XQ: Alteration of thrombospondin-1
and -2 in rat brains following experimental intracerebral
hemorrhage. Laboratory investigation. J Neurosurg. 113:820–825.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Bodewes TC, Johnson JM, Auster M, Huynh C,
Muralidharan S, Contreras M, LoGerfo FW and Pradhan-Nabzdyk L:
Intraluminal delivery of thrombospondin-2 small interfering RNA
inhibits the vascular response to injury in a rat carotid balloon
angioplasty model. FASEB J. 31:109–119. 2017. View Article : Google Scholar
|
|
83
|
Woo MS, Yang J, Beltran C and Cho S: Cell
surface CD36 protein in monocyte/macrophage contributes to
phagocytosis during the resolution phase of ischemic stroke in
mice. J Biol Chem. 291:23654–23661. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Kim CW, Pokutta-Paskaleva A, Kumar S,
Timmins LH, Morris AD, Kang DW, Dalal S, Chadid T, Kuo KM, Raykin
J, et al: Disturbed flow promotes arterial stiffening through
thrombospondin-1. Circulation. 136:1217–1232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Moura R, Tjwa M, Vandervoort P, Van
Kerckhoven S, Holvoet P and Hoylaerts MF: Thrombospondin-1
deficiency accelerates atherosclerotic plaque maturation in
ApoE−/− mice. Circ Res. 103:1181–1189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Narizhneva NV, Razorenova OV, Podrez EA,
Chen J, Chandrasekharan UM, DiCorleto PE, Plow EF, Topol EJ and
Byzova TV: Thrombospondin-1 up-regulates expression of cell
adhesion molecules and promotes monocyte binding to endothelium.
FASEB J. 19:1158–1160. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Roth JJ, Gahtan V, Brown JL, Gerhard C,
Swami VK, Rothman VL, Tulenko TN and Tuszynski GP: Thrombospondin-1
is elevated with both intimal hyperplasia and hypercholesterolemia.
J Surg Res. 74:11–16. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Muraishi A, Capuzzi DM and Tuszynski GP:
Binding of thrombospondin to human plasma lipoproteins. Biochem
Biophys Res Commun. 193:1145–1151. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Barillari G, Iovane A, Bonuglia M,
Albonici L, Garofano P, Di Campli E, Falchi M, Condò I, Manzari V
and Ensoli B: Fibroblast growth factor-2 transiently activates the
p53 oncosuppressor protein in human primary vascular smooth muscle
cells: Implications for atherogenesis. Atherosclerosis.
210:400–406. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Osada-Oka M, Ikeda T, Akiba S and Sato T:
Hypoxia stimulates the autocrine regulation of migration of
vascular smooth muscle cells via HIF-1alpha-dependent expression of
thrombospondin-1. J Cell Biochem. 104:1918–1926. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Takahashi M, Oka M, Ikeda T, Akiba S and
Sato T: Role of thrombospondin-1 in hypoxia-induced migration of
human vascular smooth muscle cells. Yakugaku Zasshi. 128:377–383.
2008.(In Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Yabkowitz R, Mansfield PJ, Ryan US and
Suchard SJ: Thrombospondin mediates migration and potentiates
platelet-derived growth factor-dependent migration of calf
pulmonary artery smooth muscle cells. J Cell Physiol. 157:24–32.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Raman P, Krukovets I, Marinic TE,
Bornstein P and Stenina OI: Glycosylation mediates up-regulation of
a potent antiangiogenic and proatherogenic protein,
thrombospondin-1, by glucose in vascular smooth muscle cells. J
Biol Chem. 282:5704–5714. 2007. View Article : Google Scholar
|
|
94
|
Stenina OI, Krukovets I, Wang K, Zhou Z,
Forudi F, Penn MS, Topol EJ and Plow EF: Increased expression of
thrombospondin-1 in vessel wall of diabetic Zucker rat.
Circulation. 107:3209–3215. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Ganguly R, Sahu S, Ohanyan V, Haney R,
Chavez RJ, Shah S, Yalamanchili S and Raman P: Oral chromium
picolinate impedes hyperglycemia-induced atherosclerosis and
inhibits proatherogenic protein TSP-1 expression in STZ-induced
type 1 diabetic ApoE−/− mice. Sci Rep. 7:452792017.
View Article : Google Scholar
|
|
96
|
Yang YJ, Cheng DY, Zheng XW, Li F and Yang
GL: Expression of thrombospondin-1 in the lung of hypoxic pulmonary
hypertension rats. Sichuan Da Xue Xue Bao Yi Xue Ban. 43:19–23.
2012.(In Chinese). PubMed/NCBI
|
|
97
|
Reed MJ, Iruela-Arispe L, O’Brien ER,
Truong T, LaBell T, Bornstein P and Sage EH: Expression of
thrombospondins by endothelial cells. Injury is correlated with
TSP-1. Am J Pathol. 147:1068–1080. 1995.PubMed/NCBI
|
|
98
|
DiPietro LA, Nebgen DR and Polverini PJ:
Downregulation of endothelial cell thrombospondin 1 enhances in
vitro angiogenesis. J Vasc Res. 31:178–185. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Dardik R, Solomon A, Loscalzo J, Eskaraev
R, Bialik A, Goldberg I, Schiby G and Inbal A: Novel proangiogenic
effect of factor XIII associated with suppression of thrombospondin
1 expression. Arterioscler Thromb Vasc Biol. 23:1472–1477. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Isenberg JS, Hyodo F, Ridnour LA, Shannon
CS, Wink DA, Krishna MC and Roberts DD: Thrombospondin 1 and
vasoactive agents indirectly alter tumor blood flow. Neoplasia.
10:886–896. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Tzeng HT, Tsai CH, Yen YT, Cheng HC, Chen
YC, Pu SW, Wang YS, Shan YS, Tseng YL, Su WC, et al: Dysregulation
of Rab37-mediated cross-talk between cancer cells and endothelial
cells via thrombospondin-1 promotes tumor neovasculature and
metastasis. Clin Cancer Res. 23:2335–2345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Bitar MS: Diabetes impairs angiogenesis
and induces endothelial cell senescence by up-regulating
thrombospondin-CD47-dependent signaling. Int J Mol Sci.
20:E6732019. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Yafai Y, Eichler W, Iandiev I, Unterlauft
JD, Jochmann C, Wiedemann P and Bringmann A: Thrombospondin-1 is
produced by retinal glial cells and inhibits the growth of vascular
endothelial cells. Ophthalmic Res. 52:81–88. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Wang S, Sorenson CM and Sheibani N: Lack
of thrombospondin 1 and exacerbation of choroidal
neovascularization. Arch Ophthalmol. 130:615–620. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Wu Z, Wang S, Sorenson CM and Sheibani N:
Attenuation of retinal vascular development and neovascularization
in transgenic mice over-expressing thrombospondin-1 in the lens.
Dev Dyn. 235:1908–1920. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wang Y, Wang S and Sheibani N: Enhanced
proangiogenic signaling in thrombospondin-1-deficient retinal
endothelial cells. Microvasc Res. 71:143–151. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wang S, Wu Z, Sorenson CM, Lawler J and
Sheibani N: Thrombospondin-1-deficient mice exhibit increased
vascular density during retinal vascular development and are less
sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn.
228:630–642. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Sheibani N, Sorenson CM, Cornelius LA and
Frazier WA: Thrombospondin-1, a natural inhibitor of angiogenesis,
is present in vitreous and aqueous humor and is modulated by
hyperglycemia. Biochem Biophys Res Commun. 267:257–261. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Koch M, Hussein F, Woeste A, Gründker C,
Frontzek K, Emons G and Hawighorst T: CD36-mediated activation of
endothelial cell apoptosis by an N-terminal recombinant fragment of
thrombospondin-2 inhibits breast cancer growth and metastasis in
vivo. Breast Cancer Res Treat. 128:337–346. 2011. View Article : Google Scholar
|
|
110
|
Tomii Y, Kamochi J, Yamazaki H, Sawa N,
Tokunaga T, Ohnishi Y, Kijima H, Ueyama Y, Tamaoki N and Nakamura
M: Human thrombospondin 2 inhibits proliferation of microvascular
endothelial cells. Int J Oncol. 20:339–342. 2002.PubMed/NCBI
|
|
111
|
Armstrong LC, Bjorkblom B, Hankenson KD,
Siadak AW, Stiles CE and Bornstein P: Thrombospondin 2 inhibits
microvascular endothelial cell proliferation by a
caspase-independent mechanism. Mol Biol Cell. 13:1893–1905. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Kyriakides TR, Zhu YH, Yang Z, Huynh G and
Bornstein P: Altered extracellular matrix remodeling and
angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am
J Pathol. 159:1255–1262. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Calabro NE, Kristofik NJ and Kyriakides
TR: Thrombospondin-2 and extracellular matrix assembly. Biochim
Biophys Acta. 1840.2396–2402. 2014.
|
|
114
|
Krady MM, Zeng J, Yu J, MacLauchlan S,
Skokos EA, Tian W, Bornstein P, Sessa WC and Kyriakides TR:
Thrombospondin-2 modulates extracellular matrix remodeling during
physiological angiogenesis. Am J Pathol. 173:879–891. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Park YW, Kang YM, Butterfield J, Detmar M,
Goronzy JJ and Weyand CM: Thrombospondin 2 functions as an
endogenous regulator of angiogenesis and inflammation in rheumatoid
arthritis. Am J Pathol. 165:2087–2098. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Agah A, Kyriakides TR, Letrondo N,
Bjorkblom B and Bornstein P: Thrombospondin 2 levels are increased
in aged mice: Consequences for cutaneous wound healing and
angiogenesis. Matrix Biol. 22:539–547. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Feige JJ: Thrombospondins: Multimodular
proteins with angiostatic function. Pathol Biol (Paris).
47:339–344. 1999.(In French).
|
|
118
|
Raugi GJ, Mullen JS, Bark DH, Okada T and
Mayberg MR: Thrombospondin deposition in rat carotid artery injury.
Am J Pathol. 137:179–185. 1990.PubMed/NCBI
|
|
119
|
Lemkens P, Boari G, Fazzi G, Janssen G,
Murphy-Ullrich J, Schiffers P and De Mey J: Thrombospondin-1 in
early flow-related remodeling of mesenteric arteries from young
normotensive and spontaneously hypertensive rats. Open Cardiovasc
Med J. 6:50–59. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Ichii T, Koyama H, Tanaka S, Shioi A,
Okuno Y, Otani S and Nishizawa Y: Thrombospondin-1 mediates smooth
muscle cell proliferation induced by interaction with human
platelets. Arterioscler Thromb Vasc Biol. 22:1286–1292. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Riessen R, Kearney M, Lawler J and Isner
JM: Immunolocalization of thrombospondin-1 in human atherosclerotic
and restenotic arteries. Am Heart J. 135:357–364. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Yoshida S, Nabzdyk CS, Pradhan L and
LoGerfo FW: Thrombospondin-2 gene silencing in human aortic smooth
muscle cells improves cell attachment. J Am Coll Surg. 213:668–676.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Ochoa CD, Yu L, Al-Ansari E, Hales CA and
Quinn DA: Thrombospondin-1 null mice are resistant to
hypoxia-induced pulmonary hypertension. J Cardiothorac Surg.
5:322010. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Satoh M, Nasu T, Osaki T and Hitomi S:
Thrombospondin-1 contributes to slower aortic aneurysm growth by
inhibiting maladaptive remodeling of extracellular matrix. Clin Sci
(Lond). 131:1283–1285. 2017. View Article : Google Scholar
|
|
125
|
Liu Z, Morgan S, Ren J, Wang Q, Annis DS,
Mosher DF, Zhang J, Sorenson CM, Sheibani N and Liu B:
Thrombospondin-1 (TSP1) contributes to the development of vascular
inflammation by regulating monocytic cell motility in mouse models
of abdominal aortic aneurysm. Circ Res. 117:129–141. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Cointe S, Rheaume E, Martel C, Blanc-Brude
O, Dubé E, Sabatier F, Dignat-George F, Tardif JC and Bonnefoy A:
Thrombospondin-1-derived peptide RFYVVMWK improves the adhesive
phenotype of CD34(+) cells from atherosclerotic patients with type
2 diabetes. Cell Transplant. 26:327–337. 2017. View Article : Google Scholar :
|
|
127
|
Kyriakides TR, Rojnuckarin P, Reidy MA,
Hankenson KD, Papayannopoulou T, Kaushansky K and Bornstein P:
Megakaryocytes require thrombospondin-2 for normal platelet
formation and function. Blood. 101:3915–3923. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Kyriakides TR, Leach KJ, Hoffman AS,
Ratner BD and Bornstein P: Mice that lack the angiogenesis
inhibitor, thrombospondin 2, mount an altered foreign body reaction
characterized by increased vascularity. Proc Natl Acad Sci USA.
96:4449–4454. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Roberts DD, Haverstick DM, Dixit VM,
Frazier WA, Santoro SA and Ginsburg V: The platelet glycoprotein
thrombospondin binds specifically to sulfated glycolipids. J Biol
Chem. 260:9405–9411. 1985.PubMed/NCBI
|
|
130
|
Yang S, Song R, Li X, Zhang T, Fu J and
Cui X: Thrombospondin-2 predicts response to treatment with
intravenous immunoglobulin in children with Kawasaki disease. BMJ
Paediatr Open. 2:e0001902018. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Reinecke H, Robey TE, Mignone JL, Muskheli
V, Bornstein P and Murry CE: Lack of thrombospondin-2 reduces
fibrosis and increases vascularity around cardiac cell grafts.
Cardiovasc Pathol. 22:91–95. 2013. View Article : Google Scholar
|
|
132
|
Roberts DD: Interactions of thrombospondin
with sulfated glycolipids and proteoglycans of human melanoma
cells. Cancer Res. 48:6785–6793. 1988.PubMed/NCBI
|
|
133
|
Orr AW, Pedraza CE, Pallero MA, Elzie CA,
Goicoechea S, Strickland DK and Murphy-Ullrich JE: Low density
lipoprotein receptor-related protein is a calreticulin coreceptor
that signals focal adhesion disassembly. J Cell Biol.
161:1179–1189. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Li Z, Calzada MJ, Sipes JM, Cashel JA,
Krutzsch HC, Annis DS, Mosher DF and Roberts DD: Interactions of
thrombospondins with alpha4beta1 integrin and CD47 differentially
modulate T cell behavior. J Cell Biol. 157:509–519. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Huang Z, Newcomb CJ, Lei Y, Zhou Y,
Bornstein P, Amendt BA, Stupp SI and Snead ML: Bioactive nanofibers
enable the identification of thrombospondin 2 as a key player in
enamel regeneration. Biomaterials. 61:216–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Lawler J and Hynes RO: An integrin
receptor on normal and thrombasthenic platelets that binds
thrombospondin. Blood. 74:2022–2027. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Kong P, Cavalera M and Frangogiannis NG:
The role of thrombospondin (TSP)-1 in obesity and diabetes.
Adipocyte. 3:81–84. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Hogg PJ, Hotchkiss KA, Jimenez BM,
Stathakis P and Chesterman CN: Interaction of platelet-derived
growth factor with thrombospondin 1. Biochem J. 326:709–716. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Qian X, Wang TN, Rothman VL, Nicosia RF
and Tuszynski GP: Thrombospondin-1 modulates angiogenesis in vitro
by up-regulation of matrix metalloproteinase-9 in endothelial
cells. Exp Cell Res. 235:403–412. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Liu A, Garg P, Yang S, Gong P, Pallero MA,
Annis DS, Liu Y, Passaniti A, Mann D, Mosher DF, et al: Epidermal
growth factor-like repeats of thrombospondins activate
phospholipase Cgamma and increase epithelial cell migration through
indirect epidermal growth factor receptor activation. J Biol Chem.
284:6389–6402. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Zheng B and Clemmons DR: Blocking ligand
occupancy of the alphaVbeta3 integrin inhibits insulin-like growth
factor I signaling in vascular smooth muscle cells. Proc Natl Acad
Sci USA. 95:11217–11222. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Saumet A, Slimane MB, Lanotte M, Lawler J
and Dubernard V: Type 3 repeat/C-terminal domain of
thrombospondin-1 triggers caspase-independent cell death through
CD47/alphavbeta3 in promyelocytic leukemia NB4 cells. Blood.
106:658–667. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Isenberg JS, Jia Y, Fukuyama J, Switzer
CH, Wink DA and Roberts DD: Thrombospondin-1 inhibits nitric oxide
signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem.
282:15404–15415. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Lagadec P, Dejoux O, Ticchioni M, Cottrez
F, Johansen M, Brown EJ and Bernard A: Involvement of a
CD47-dependent pathway in platelet adhesion on inflamed vascular
endothelium under flow. Blood. 101:4836–4843. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Mandler WK, Nurkiewicz TR, Porter DW,
Kelley EE and Olfert IM: Microvascular dysfunction following
multiwalled carbon nanotube exposure is mediated by
thrombospondin-1 receptor CD47. Toxicol Sci. 165:90–99. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Gao Q, Chen K, Gao L, Zheng Y and Yang YG:
Thrombospondin-1 signaling through CD47 inhibits cell cycle
progression and induces senescence in endothelial cells. Cell Death
Dis. 7:e23682016. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Yamauchi Y, Kuroki M, Imakiire T, Uno K,
Abe H, Beppu R, Yamashita Y, Kuroki M and Shirakusa T: Opposite
effects of thrombospondin-1 via CD36 and CD47 on homotypic
aggregation of monocytic cells. Matrix Biol. 21:441–448. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Kaur S, Chang T, Singh SP, Lim L, Mannan
P, Garfield SH, Pendrak ML, Soto-Pantoja DR, Rosenberg AZ, Jin S
and Roberts DD: CD47 signaling regulates the immunosuppressive
activity of VEGF in T cells. J Immunol. 193:3914–3924. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Rogers NM, Roberts DD and Isenberg JS:
Age-associated induction of cell membrane CD47 limits basal and
temperature-induced changes in cutaneous blood flow. Ann Surg.
258:184–191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Rogers NM, Sharifi-Sanjani M, Csanyi G,
Pagano PJ and Isenberg JS: Thrombospondin-1 and CD47 regulation of
cardiac, pulmonary and vascular responses in health and disease.
Matrix Biol. 37:92–101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Csanyi G, Feck DM, Ghoshal P, Singla B,
Lin H, Nagarajan S, Meijles DN, Al Ghouleh I, Cantu-Medellin N,
Kelley EE, et al: CD47 and Nox1 mediate dynamic fluid-phase
macropinocytosis of native LDL. Antioxid Redox Signal. 26:886–901.
2017. View Article : Google Scholar :
|
|
152
|
Rogers NM, Sharifi-Sanjani M, Yao M,
Ghimire K, Bienes-Martinez R, Mutchler SM, Knupp HE, Baust J,
Novelli EM, Ross M, et al: TSP1-CD47 signaling is upregulated in
clinical pulmonary hypertension and contributes to pulmonary
arterial vasculopathy and dysfunction. Cardiovasc Res. 113:15–29.
2017. View Article : Google Scholar
|
|
153
|
Kellouche S, Mourah S, Bonnefoy A,
Schoëvaert D, Podgorniak MP, Calvo F, Hoylaerts MF, Legrand C and
Dosquet C: Platelets, thrombospondin-1 and human dermal fibroblasts
cooperate for stimulation of endothelial cell tubulogenesis through
VEGF and PAI-1 regulation. Exp Cell Res. 313:486–499. 2007.
View Article : Google Scholar
|
|
154
|
Murphy-Ullrich JE and Poczatek M:
Activation of latent TGF-beta by thrombospondin-1: Mechanisms and
physiology. Cytokine Growth Factor Rev. 11:59–69. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Schultz-Cherry S, Lawler J and
Murphy-Ullrich JE: The type 1 repeats of thrombospondin 1 activate
latent transforming growth factor-beta. J Biol Chem.
269:26783–26788. 1994.PubMed/NCBI
|
|
156
|
Rosini S, Pugh N, Bonna AM, Hulmes DJS,
Farndale RW and Adams JC: Thrombospondin-1 promotes matrix
homeostasis by interacting with collagen and lysyl oxidase
precursors and collagen cross-linking sites. Sci Signal.
11:eaar25662018. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Yang Z, Strickland DK and Bornstein P:
Extracellular matrix metalloproteinase 2 levels are regulated by
the low density lipoprotein-related scavenger receptor and
thrombospondin 2. J Biol Chem. 276:8403–8408. 2001. View Article : Google Scholar
|
|
158
|
Nakamura M, Oida Y, Abe Y, Yamazaki H,
Mukai M, Matsuyama M, Chijiwa T, Matsumoto H and Ueyama Y:
Thrombospondin-2 inhibits tumor cell invasion through the
modulation of MMP-9 and uPA in pancreatic cancer cells. Mol Med
Rep. 1:423–427. 2008.PubMed/NCBI
|
|
159
|
Murphy-Ullrich JE and Mosher DF:
Interactions of thrombospondin with endothelial cells:
Receptor-mediated binding and degradation. J Cell Biol.
105:1603–1611. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Godyna S, Liau G, Popa I, Stefansson S and
Argraves WS: Identification of the low density lipoprotein
receptor-related protein (LRP) as an endocytic receptor for
thrombospondin-1. J Cell Biol. 129:1403–1410. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Mikhailenko I, Kounnas MZ and Strickland
DK: Low density lipoprotein receptor-related protein/alpha
2-macroglobulin receptor mediates the cellular internalization and
degradation of thrombospondin. A process facilitated by
cell-surface proteoglycans. J Biol Chem. 270:9543–9549. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Daviet L and McGregor JL: Vascular biology
of CD36: Roles of this new adhesion molecule family in different
disease states. Thromb Haemost. 78:65–69. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Ramanathan S, Mazzalupo S, Boitano S and
Montfort WR: Thrombospondin-1 and angiotensin II inhibit soluble
guanylyl cyclase through an increase in intracellular calcium
concentration. Biochemistry. 50:7787–7799. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Trujillo G and Kew RR: Platelet-derived
thrombospondin-1 is necessary for the vitamin D-binding protein
(Gc-globulin) to function as a chemotactic cofactor for C5a. J
Immunol. 173:4130–4136. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Tang Y, Scheef EA, Wang S, Sorenson CM,
Marcus CB, Jefcoate CR and Sheibani N: CYP1B1 expression promotes
the proangiogenic phenotype of endothelium through decreased
intracellular oxidative stress and thrombospondin-2 expression.
Blood. 113:744–754. 2009. View Article : Google Scholar :
|
|
166
|
MacLauchlan S, Yu J, Parrish M, Asoulin
TA, Schleicher M, Krady MM, Zeng J, Huang PL, Sessa WC and
Kyriakides TR: Endothelial nitric oxide synthase controls the
expression of the angiogenesis inhibitor thrombospondin 2. Proc
Natl Acad Sci USA. 108:E1137–E1145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Lee NV, Sato M, Annis DS, Loo JA, Wu L,
Mosher DF and Iruela-Arispe ML: ADAMTS1 mediates the release of
antiangiogenic polypeptides from TSP1 and 2. EMBO J. 25:5270–5283.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Mead TJ and Apte SS: ADAMTS proteins in
human disorders. Matrix Biol. 71–72:225–239. 2018. View Article : Google Scholar
|
|
169
|
Bengtsson E, Hultman K, Duner P, Asciutto
G, Almgren P, Orho-Melander M, Melander O, Nilsson J,
Hultgardh-Nilsson A and Gonçalves I: ADAMTS-7 is associated with a
high-risk plaque phenotype in human atherosclerosis. Sci Rep.
7:37532017. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Pereira A, Palma Dos Reis R, Rodrigues R,
Sousa AC, Gomes S, Borges S, Ornelas I, Freitas AI, Guerra G,
Henriques E, et al: Association of ADAMTS7 gene polymorphism with
cardiovascular survival in coronary artery disease. Physiol
Genomics. 48:810–815. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Bauer RC, Tohyama J, Cui J, Cheng L, Yang
J, Zhang X, Ou K, Paschos GK, Zheng XL, Parmacek MS, et al:
Knockout of Adamts7, a novel coronary artery disease locus in
humans, reduces atherosclerosis in mice. Circulation.
131:1202–1213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Reilly MP, Li M, He J, Ferguson JF,
Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson
JR, et al: Identification of ADAMTS7 as a novel locus for coronary
atherosclerosis and association of ABO with myocardial infarction
in the presence of coronary atherosclerosis: Two genome-wide
association studies. Lancet. 377:383–392. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Qin W, Cao Y, Li L, Chen W and Chen X:
Upregulation of ADAMTS7 and downregulation of COMP are associated
with aortic aneurysm. Mol Med Rep. 16:5459–5463. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Kessler T, Zhang L, Liu Z, Yin X, Huang Y,
Wang Y, Fu Y, Mayr M, Ge Q, Xu Q, et al: ADAMTS-7 inhibits
re-endothelialization of injured arteries and promotes vascular
remodeling through cleavage of thrombospondin-1. Circulation.
131:1191–1201. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Pu X, Xiao Q, Kiechl S, Chan K, Ng FL, Gor
S, Poston RN, Fang C, Patel A, Senver EC, et al: ADAMTS7 cleavage
and vascular smooth muscle cell migration is affected by a
coronary-artery-disease-associated variant. Am J Hum Genet.
92:366–374. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Wang L, Zheng J, Bai X, Liu B, Liu CJ, Xu
Q, Zhu Y, Wang N, Kong W and Wang X: ADAMTS-7 mediates vascular
smooth muscle cell migration and neointima formation in
balloon-injured rat arteries. Circ Res. 104:688–698. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Wu W, Li J, Yu C, Gao Y, Fan S, Ye X, Wang
Y and Zheng J: Association of serum ADAMTS-7 levels with left
ventricular reverse remodeling after ST-elevation myocardial
infarction. Eur J Med Res. 23:152018. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Chan K, Pu X, Sandesara P, Poston RN,
Simpson IA, Quyyumi AA, Ye S and Patel RS: Genetic variation at the
ADAMTS7 locus is associated with reduced severity of coronary
artery disease. J Am Heart Assoc. 6:e0069282017. View Article : Google Scholar :
|
|
179
|
Wu W, Wang H, Yu C, Li J, Gao Y, Ke Y,
Wang Y, Zhou Y and Zheng J: Association of ADAMTS-7 levels with
cardiac function in a rat model of acute myocardial infarction.
Cell Physiol Biochem. 38:950–958. 2016. View Article : Google Scholar : PubMed/NCBI
|
